Logo
x

Search

Subscribe Now

KalVista Pharmaceuticals

KalVista Reports the US FDA’s NDA Acceptance of Sebetralstat for Treating Hereditary Angioedema (HAE)

KalVista Reports the US FDA’s NDA Acceptance of Sebetralstat for Treating Hereditary Angioedema (HAE)

  • September 3, 2024
KalVista Pharmaceuticals Highlights Results from the P-III (KONFIDENT) Study of Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals Highlights Results from the P-III (KONFIDENT) Study of Sebetralstat for Hereditary Angioedema

  • February 14, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.